Skip to NavigationSkip to content

Novartis' Cosentyx has strong Phase 3 interim showing in axial spondyloarthritis

Published on 17/09/19 at 09:44am

Novartis has highlighted new data from its ongoing Phase 3 trial into the efficacy and safety of itsinterleukin-17A inhibitor Cosentyx (secukinumab) in the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), showing that the drug met its primary endpoint and all secondary endpoints.  

Foremost among the results was the finding that, after 16 weeks, patients using Cosentyx achieved a score of 40% on the Assessment of SpondyloArthritis international Society scale, representing a “significant and clinically meaningful reduction in disease activity” compared to placebo, and meeting the trial’s primary endpoint.

The drug’s safety profile was also found to be positive, in line with previous studies.

“These study results for Cosentyx build on our long-standing experience in ankylosing spondylitis and are a step toward a new treatment option that could allow patients to realize relief much earlier in axial spondyloarthritis,” said Dr John Tsai, Head of Global Drug Development and Chief Medical Officer for Novartis. “If approved, this would be the fourth indication for Cosentyx.”

Novartis confirmed it plans to present full data from the study at an upcoming scientific congress.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches